Alzheimer’s disease (AD) is a complex disease with multiple causes. Current drugs are unsafe and ineffective. This technology is a world-leading invention of a novel multi-target therapy for AD. Our team’s trials have found that sodium benzoate can rapidly, safely, and effectively improve the cognition and overall function of patients with early AD through multiple actions, including enhancing NMDA receptor function, regulating sex hormones, increasing endogenous antioxidants, and reducing Aβ.

This technology is the world’s first multi-target Alzheimer’s disease treatment. Our randomized, double-blind, placebo-controlled trials have found that oral sodium benzoate, through its multiple effects of enhancing NMDA receptor, regulating sex hormones, increasing endogenous antioxidants, and reducing β-amyloid, improved the cognition and overall function of a wider range of Alzheimer’s patients, with a simpler administration, faster response, and greater safety than other dementia drugs.

The dementia market is huge, and new drugs are urgently needed. This technology, leading globally, provides a new approach for Alzheimer’s disease (AD). It is likely to benefit AD patients and to raise Taiwan’s international visibility. This technology has great potential to be approved as a novel treatment for dementia in the future. The product also has the opportunity to be marketed globally, not only increasing employment opportunities but also promoting the development of related new drugs.